Filing Flows

Filing Flows › 8-K events › Zentalis Pharmaceuticals

Zentalis Pharmaceuticals: results of operations

Form 8-K filed Nov 9, 2026 · items 2.02, 7.01

FDA decisionsZentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates

What the filing says

Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates • DENALI Part 1b survival data strengthen azenosertib's position as the potential first-in-class oral, non-chemotherapy, non-ADC therapy in pivotal development for Cyclin E1-positive PROC

Read the filing on SEC EDGAR →

What usually followsAcross 69,249 8-Ks reporting Item 2.02 (results of operations) in our universe, the stock's median move the next session was +0.2% (typical size ±3.6%, up 51% of the time); over the following 21 sessions, +1.2%. Every item ranked →

Zentalis Pharmaceuticals at a glance

Latest quarterQ4 2024
Revenue$26.9M
Operating margin-185.6%
IndustryPharmaceutical Preparations

Zentalis Pharmaceuticals, Q4 2024: revenue $26.9M, operating margin -185.6%. The chart follows the revenue to costs, profit and cash.

Zentalis Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent fda decisions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.